Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Post by ready2go1on Oct 16, 2012 4:32pm
259 Views
Post# 20490530

PCA3

PCA3

This company has never released any news and as I have said before, we continue to see selling secondary to fear of the unknown. I am expecting some type of news in the near term to jump start the stock and get us moving in the right direction. Why am I expecting?

all you have to do is look at the post that showed the MAYO clinic lab update for pca3. If this was not an important test, driven by patient demand, the hospitals and labs would not spend the money to train their staff, acquire the materials needed, and discuss testing options with patients. This is not the only lab update out there and I have seen several  the past 30 days here in the U.S. plus there have been 4 new European labs that have began to offer the test last week. If pca3 was not an improtant test no one would go through the process to get the test approved to run at their labs; believe me, it takes someone on the other end demanding that the lab offer the test.

I'm frustrated just like everyone else; but I am looking at a move from 8% to 16% as a double in revenue, and many that I have spoken with are now using the test 3x more than they did prior to FDA approval. At some point, this will show up.

<< Previous
Bullboard Posts
Next >>